Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 13, 2020 07:00 ET | Source: Axovant Gene Therapies

Axovant Gene Therapies Receives Rare Pediatric Disease Designation for AXO-AAV-GM2 for Tay-Sachs and Sandhoff Disease

NEW YORK, Oct. 13, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (NASDAQ: AXGT), a clinical-stage company developing innovative gene therapies for neurological diseases, today announced that...
October 09, 2020 07:00 ET | Source: Axovant Gene Therapies

Axovant Gene Therapies Receives Rare Pediatric Disease Designation for AXO-AAV-GM1 for GM1 Gangliosidosis

NEW YORK, Oct. 09, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (NASDAQ: AXGT), a clinical-stage company developing innovative gene therapies for neurological diseases, today announced that...
October 08, 2020 07:00 ET | Source: Axovant Gene Therapies

Axovant Gene Therapies Strengthens Board of Directors and Announces New Chief Commercial Officer

Kristiina Vuori, M.D., Ph.D. is a leading genetics and cancer researcher who serves as President and Board member of Sanford Burnham Prebys Medical Discovery InstituteAppointment of Dr. Vuori...
October 06, 2020 07:00 ET | Source: Axovant Gene Therapies

Axovant Announces Positive Six-Month Follow-Up Data From Second Cohort of SUNRISE-PD Phase 2 Trial of AXO-Lenti-PD Gene Therapy

• AXO-Lenti-PD was well-tolerated with no treatment-related serious adverse events at 6 months• 21-point mean improvement in UPDRS Part III “OFF” score, a 40% improvement from baseline, exceeding...
October 05, 2020 07:00 ET | Source: Axovant Gene Therapies

Axovant to Participate in Upcoming October Conferences and Provide AXO-Lenti-PD Program Update the Morning of October 6th

NEW YORK, Oct. 05, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (Nasdaq: AXGT), a clinical-stage company developing innovative gene therapies, today announced that the Company will present...
September 15, 2020 08:00 ET | Source: Axovant Gene Therapies

Axovant and Viralgen Sign Strategic Gene Therapy Development and Manufacturing Partnership

Partnership secures access to cGMP capacity and resources at Viralgen to support the development and commercialization of Axovant’s AAV gene therapy programs for GM1 and GM2 gangliosidosisPartnership...
September 08, 2020 07:30 ET | Source: Axovant Gene Therapies

Axovant Announces First Parkinson's Disease Gene Therapy R&D Day and Participation in Upcoming September Conferences"

- Parkinson’s Disease R&D Day to be hosted by Gavin Corcoran, MD, Chief R&D Officer, on October 30th, 2020, with leading movement disorder specialists NEW YORK and BASEL, Switzerland,...
August 11, 2020 07:00 ET | Source: Axovant Sciences Ltd.

Axovant Announces Corporate Updates and Financial Results for First Fiscal Quarter Ended June 30, 2020

Data readouts for AXO-Lenti-PD and AXO-AAV-GM1 remain on-track for Q4 2020Completed 3-year manufacturing and supply agreement with Oxford BioMedica for AXO-Lenti-PDCompany had $55.5 million of cash...
July 31, 2020 06:30 ET | Source: Axovant Sciences Ltd.

Axovant Signs Three-Year Clinical Supply Agreement With Oxford Biomedica for Manufacturing and Supply of AXO-Lenti-PD

NEW YORK and BASEL, Switzerland, July 31, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd (NASDAQ: AXGT), a clinical-stage company developing innovative gene therapies for neurological diseases,...
June 10, 2020 06:00 ET | Source: Axovant Sciences Ltd.

Axovant Announces Year-End Financial Results and Expected Key Clinical Milestones in Q4 2020

Completed enrollment of cohort 2 of SUNRISE-PD Phase 2 study of AXO-Lenti-PD in Parkinson’s disease, with data from this cohort expected in Q4 2020Completed enrollment of low-dose cohort of Phase 1/2...